Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 9/20 | 0.36 |
| ▸ | ACHE | P22303 | 9/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6906749 | 1.00 | MEN1 (0.41) | MEN1KMT2ACRHBPCRHR2BCHE | |
| SCHEMBL6336995 | 0.82 | PARP1 (0.47) | MEN1KMT2ACRHBPCRHR2BCHE | |
| SCHEMBL6333422 | 0.82 | PARP1 (0.47) | MEN1KMT2ACRHBPCRHR2BCHE | |
| SCHEMBL6635272 | 0.78 | PARP1 (0.45) | MEN1KMT2ACRHBPCRHR2ITGA4 | |
| SCHEMBL6341433 | 0.75 | ALDH1A1 (0.44) | MEN1KMT2ACRHBPCRHR2BCHE | |
| SCHEMBL7204176 | 0.75 | ALDH1A1 (0.44) | MEN1KMT2ACRHBPCRHR2BCHE | |
| SCHEMBL6334919 | 0.75 | KMT2A (0.45) | MEN1KMT2ACRHBPCRHR2BCHE | |
| SCHEMBL7006162 | 0.75 | KMT2A (0.45) | MEN1KMT2ACRHBPCRHR2BCHE | |
| SCHEMBL6540897 | 0.73 | MEN1 (0.46) | MEN1KMT2ACRHBPCRHR2BCHE | |
| SCHEMBL6342999 | 0.71 | KMT2A (0.40) | MEN1KMT2ACRHBPCRHR2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-04 | — | — | US | disclosed |
| EP-1368343-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002055518-A1 | 1-(2-METHOXYBENZYL)-3-BENZHYDRYLPIPERAZINES AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220403-A1 | 1-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonists | BDKRB1, BDKRB2, TACR1 | MEN1 442/4885KMT2A 1539/4885CRHBP 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.